Hemab Therapeutics Holdings, Inc. (COAG)

COAG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	87.97	74.41
Short-Term Investments	97.51	13.92
Cash & Cash Equivalents	185.49	88.33
Cash Growth	110.00%	-
Other Current Assets	7.07	4.91
Total Current Assets	192.55	93.24
Property, Plant & Equipment	0.61	0.9
Goodwill and Intangibles	1.09	1.67
Other Long-Term Assets	0.53	0.48
Total Long-Term Assets	2.23	3.04
Total Assets	194.78	96.28
Accounts Payable	5.73	3.16
Current Debt	0.65	0.67
Other Current Liabilities	4.3	2.86
Total Current Liabilities	10.68	6.69
Long-Term Debt	0.57	1.06
Other Long-Term Liabilities	0	0.06
Total Long-Term Liabilities	0.57	1.12
Total Liabilities	11.25	7.8
Total Debt	1.22	1.73
Debt Growth	-29.28%	-
Retained Earnings	-181.86	-117.95
Comprehensive Income	0.18	-0.37
Shareholders' Equity	-176.64	-115.27
Net Cash (Debt)	184.27	86.6
Net Cash (Debt) Growth	112.78%	-
Working Capital	181.87	86.55

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).